PDE10A
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A
As of the edition of 20 October 2026, PDE10A (cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A, UniProt Q9Y233) has 5 drugs tested at it and 5 companies on the list, 4 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9Y233
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 359
- Disease areas
- Mental health; Nervous system; Inherited and neonatal; Cancer
- Registered trials of its drugs
- 30
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Went quiet | 1 |
| Stopped | 3 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| MK-8189 | Active | Phase 2 | none listed |
| Mardepodect | Stopped | Phase 2 | none listed |
| Balipodect | Went quiet | Phase 2 | none listed |
| PBF-999 | Stopped | Phase 1 | none listed |
| AMG 579 | Stopped | Phase 1 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Engaged | 1 |
| Total on the list | 5 |
The other 2 companies at PDE10A
In the product5 companies in all; 2 are not named here, and no score is.
See the 5 companies at PDE10A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.